Myopia and Pediatric Myopia Progression: Market View

This reports provides a data-driven overview of the current and future competitive landscape in Myopia and Pediatric Myopia Progression Therapeutics.

• In 2024 and 2029, China is anticipated to have the highest number of total prevalent adult cases of myopia, representing a large portion of global cases.
• Currently, myopia and pediatric myopia progression have no FDA-approved drug for treatment. Atropine sulfate is the primary established treatment prescribed for significantly slowing axial eye growth and preventing myopia from getting worse.
• The myopia and pediatric myopia progression pipeline holds 28 molecules, with three assets in the pre-registration stage, nine assets in Phase III development, and another seven in Phase II.
• Over the past decade, 286 clinical trials were conducted on myopia and pediatric myopia progression. The year with the most studies initiated was 2021, with 38 trials, followed by 2023 with 37 trials.
• During the past 34 months, one merger and acquisition and seven strategic alliances involving companies developing myopia and pediatric myopia progression assets were completed globally.
• The myopia and pediatric myopia progression market is likely to see an influx of drugs in the near term, with two products in pre-registration and nine products in Phase III development.

Scope

GlobalData's Myopia and Pediatric Myopia Progression: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Myopia and Pediatric Myopia Progression Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myopia and Pediatric Myopia Progression Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.